Search research articles
Contact Us
Filters
Showing results (171-180 of 234) with videos related to
Page
of 24
Sort By:
The Lancet. Oncology
|
May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
Nature Medicine
|
March 2, 2016
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar, Ilsa Coleman, Colm Morrissey, et al.
Prostate Cancer and Prostatic Diseases
|
November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Clinical Genitourinary Cancer
|
September 12, 2024
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Dimitra Rafailia Bakaloudi, Elizabeth L Koehne, Leonidas N Diamantopoulos, et al.
The Journal of Clinical Investigation
|
July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
Mark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Genitourinary Cancer
|
November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program
Leonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
The Lancet. Oncology
|
November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C Araujo, Géralyn C Trudel, Fred Saad, et al.
Page
of 24
Search research articles
Search
Showing results (171-180 of 234) with videos related to
Sort By:
Page
of 24
The Lancet. Oncology
|
May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
European Urology Oncology
|
February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
Nature Medicine
|
March 2, 2016
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Akash Kumar, Ilsa Coleman, Colm Morrissey, et al.
Prostate Cancer and Prostatic Diseases
|
November 2, 2025
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
Evan Y Yu, Hiroyoshi Suzuki, Christopher M Pieczonka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 2, 2016
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial
Daniel P Petrylak, Scott T Tagawa, Manish Kohli, et al.
Clinical Genitourinary Cancer
|
September 12, 2024
Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Dimitra Rafailia Bakaloudi, Elizabeth L Koehne, Leonidas N Diamantopoulos, et al.
The Journal of Clinical Investigation
|
July 31, 2019
Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer
Mark P Labrecque, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Genitourinary Cancer
|
November 8, 2020
Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program
Leonidas N Diamantopoulos, Sarah K Holt, Ali R Khaki, et al.
The Lancet. Oncology
|
November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C Araujo, Géralyn C Trudel, Fred Saad, et al.
Page
of 24